WCLC 2025 - Posters & ePosters-P3.18.53 Phase 3 Clinical Trial ResQ201A of N-803 (NAI), Tislelizumab and Docetaxel Vs. Docetaxel Monotherapy for Advanced NSCLC Resistant to ICI Therapy

P3.18.53 Phase 3 Clinical Trial ResQ201A of N-803 (NAI), Tislelizumab and Docetaxel Vs. Docetaxel Monotherapy for Advanced NSCLC Resistant to ICI Therapy

Back to course

Asset Subtitle

sandeep reddy

Meta Tag

Speaker sandeep reddy

Topic Clinical Trials in Progress